Bangladesh's Beximco to sell generic version of Merck COVID-19 pill

Reuters2021-11-09

Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday. The...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

YYKTAN
2021-11-09
YYKTAN
Latest
26629536
2021-11-09
26629536
Ok
- 26629536:
  [Doubt]
- 26629536:
  [Strong]
- 26629536:
  [OK]
- 26629536:
  [Applaud]
- 26629536:
  [Bless]
XWB
2021-11-09
XWB
Ok
userTesting
2021-11-09
userTesting
Ok
- jc0110:
  ok

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1137172640?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-09 16:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137172640","market":"us","top_or_hot":-1,"title":"Bangladesh's Beximco to sell generic version of Merck COVID-19 pill","media":"Reuters","content":"<div>\n<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.\nThe...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html\">网页链接</a>\n\n</div>\n","source":"lsy1612507957220","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bangladesh's Beximco to sell generic version of Merck COVID-19 pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBangladesh's Beximco to sell generic version of Merck COVID-19 pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-09 16:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.\nThe...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html","article_id":"1137172640","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137172640","pubTimestamp":1636447803,"sourceInfo":{"source_id":"lsy1612507957220","name":"finance.yahoo"},"weMediaInfo":null,"summary":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of M","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东"},"translate_title":"孟加拉Beximco将出售仿制版默沙东新冠肺炎药丸","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9},"content_text":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.\nThe announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.\nMolnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.\nBeximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.\nMerck did not immediately respond to a request for comment.\nThe U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.\nThese include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.\nBeximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.\nIts London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":844421187,"gmtCreate":1636453082167,"gmtModify":1636453197612,"author":{"id":"3586858995147972","authorId":"3586858995147972","name":"YYKTAN","avatar":"https://static.tigerbbs.com/e9c7bf12299d79e1cacc0c24919b7a3c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3586858995147972","authorIdStr":"3586858995147972"},"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844421187","repostId":1137172640,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":844497531,"gmtCreate":1636449792898,"gmtModify":1636450017028,"author":{"id":"3586053412837856","authorId":"3586053412837856","name":"26629536","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586053412837856","authorIdStr":"3586053412837856"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":5,"commentSize":14,"repostSize":0,"link":"https://laohu8.com/post/844497531","repostId":1137172640,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6510754,"gmtCreate":1636450016979,"gmtModify":1636450017008,"authorId":3586053412837856,"author":{"id":3586053412837856,"idStr":"3586053412837856","authorId":3586053412837856,"name":"26629536","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":844497531,"type":1,"supId":0,"prevId":0,"content":"[Doubt]","text":"[Doubt]","html":"[Doubt]"},{"id":6510751,"gmtCreate":1636450008270,"gmtModify":1636450008358,"authorId":3586053412837856,"author":{"id":3586053412837856,"idStr":"3586053412837856","authorId":3586053412837856,"name":"26629536","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":844497531,"type":1,"supId":0,"prevId":0,"content":"[Strong]","text":"[Strong]","html":"[Strong]"},{"id":6510748,"gmtCreate":1636449999473,"gmtModify":1636449999563,"authorId":3586053412837856,"author":{"id":3586053412837856,"idStr":"3586053412837856","authorId":3586053412837856,"name":"26629536","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":844497531,"type":1,"supId":0,"prevId":0,"content":"[OK]","text":"[OK]","html":"[OK]"},{"id":6510745,"gmtCreate":1636449989907,"gmtModify":1636449989936,"authorId":3586053412837856,"author":{"id":3586053412837856,"idStr":"3586053412837856","authorId":3586053412837856,"name":"26629536","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":844497531,"type":1,"supId":0,"prevId":0,"content":"[Applaud]","text":"[Applaud]","html":"[Applaud]"},{"id":6510744,"gmtCreate":1636449983894,"gmtModify":1636449983923,"authorId":3586053412837856,"author":{"id":3586053412837856,"idStr":"3586053412837856","authorId":3586053412837856,"name":"26629536","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":844497531,"type":1,"supId":0,"prevId":0,"content":"[Bless]","text":"[Bless]","html":"[Bless]"}],"langContent":"CN"},{"id":844403976,"gmtCreate":1636448607818,"gmtModify":1636448608108,"author":{"id":"4087443275212920","authorId":"4087443275212920","name":"XWB","avatar":"https://static.tigerbbs.com/4ef27121d1015c7d31eb417553b2e797","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087443275212920","authorIdStr":"4087443275212920"},"htmlText":"&nbsp;Ok","listText":"&nbsp;Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844403976","repostId":1137172640,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":844574653,"gmtCreate":1636448174465,"gmtModify":1636448174630,"author":{"id":"4088669104286650","authorId":"4088669104286650","name":"userTesting","avatar":"https://static.tigerbbs.com/3b24fe7742aefda3019ec9856567b065","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4088669104286650","authorIdStr":"4088669104286650"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/844574653","repostId":1137172640,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6510523,"gmtCreate":1636448543073,"gmtModify":1636448543183,"authorId":3576885233950935,"author":{"id":3576885233950935,"idStr":"3576885233950935","authorId":3576885233950935,"name":"jc0110","avatar":"https://static.tigerbbs.com/e09e5e2e4ea456938e5df81fb0919107","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":844574653,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":38,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137172640"}